| scholarly article | Q13442814 |
| P50 | author | Ralph H. Hruban | Q21063634 |
| Charles J Yeo | Q96191880 | ||
| Michiel S. van der Heijden | Q96950806 | ||
| P2093 | author name string | Scott E Kern | |
| P433 | issue | 10 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| Fanconi anemia | Q845779 | ||
| P304 | page(s) | 2585-2588 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Fanconi anemia gene mutations in young-onset pancreatic cancer | |
| P478 | volume | 63 |
| Q36023352 | Advances in counselling and surveillance of patients at risk for pancreatic cancer |
| Q34635042 | Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. |
| Q33924952 | Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery |
| Q33383292 | Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma |
| Q36784879 | Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas |
| Q35640794 | Association of breast cancer susceptibility variants with risk of pancreatic cancer |
| Q38441095 | Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer |
| Q37291172 | Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. |
| Q42374449 | DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway |
| Q39916226 | Defects of FA/BRCA pathway in lymphoma cell lines |
| Q34566631 | Elevated DNA damage response in pancreatic cancer |
| Q37141651 | Emerging molecular biology of pancreatic cancer |
| Q34426529 | Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles |
| Q24301340 | FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway |
| Q26801415 | Familial Pancreatic Adenocarcinoma |
| Q89884126 | Familial Pancreatic Cancer: Current Perspectives |
| Q57643835 | Familial pancreatic cancer |
| Q80060492 | Familial pancreatic cancer |
| Q38016055 | Familial pancreatic cancer--current knowledge |
| Q38129237 | Familial pancreatic cancer—status quo |
| Q36737616 | Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma |
| Q92002816 | Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets |
| Q49616542 | Fanconi anaemia and cancer: an intricate relationship |
| Q37865169 | Fanconi anaemia: from a monogenic disease to sporadic cancer |
| Q26852818 | Fanconi anemia pathway defects in inherited and sporadic cancers |
| Q35102998 | Functional defects in the fanconi anemia pathway in pancreatic cancer cells |
| Q24563629 | Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin |
| Q56766232 | Genetic Counselors' Experiences Regarding Communication of Reproductive Risks with Autosomal Recessive Conditions found on Cancer Panels |
| Q37230991 | Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine |
| Q37148201 | Genetic and epigenetic alterations of familial pancreatic cancers |
| Q34630956 | Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project |
| Q39699084 | Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents |
| Q34589293 | Genetics and pathology of pancreatic cancer |
| Q64277715 | Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer |
| Q26781443 | Genomic alterations in pancreatic cancer and their relevance to therapy |
| Q57165768 | Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts |
| Q42700671 | Germline mutations in pancreatic cancer and potential new therapeutic options. |
| Q52330247 | Heterozygous carriers of galactocerebrosidase mutations that cause Krabbe disease have impaired microglial function and defective repair of myelin damage |
| Q39869741 | Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects |
| Q36328508 | Identifying molecular markers for the early detection of pancreatic neoplasia |
| Q37408967 | Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy |
| Q38796779 | Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis |
| Q49833942 | Inhibition of non-homologous end joining in Fanconi Anemia cells results in rescue of survival after interstrand crosslinks but sensitization to replication associated double-strand breaks |
| Q28073673 | Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? |
| Q37620679 | Metabolism addiction in pancreatic cancer |
| Q35769993 | Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. |
| Q36485336 | Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts |
| Q30438241 | Molecular pathogenesis of Fanconi anemia |
| Q37088011 | Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs) |
| Q41279772 | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. |
| Q36778113 | PARI overexpression promotes genomic instability and pancreatic tumorigenesis |
| Q33781071 | Pancreatic cancer genomics: insights and opportunities for clinical translation |
| Q30490247 | Pancreatic cancer. |
| Q26799714 | Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies |
| Q37125627 | Pancreatic carcinogenesis |
| Q34093790 | Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection |
| Q37826009 | Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic |
| Q37343314 | Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk |
| Q36372625 | Precursors to pancreatic cancer |
| Q34502557 | RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC). |
| Q98465820 | Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer |
| Q53251543 | Strategies for screening for pancreatic adenocarcinoma in high-risk patients: the place of endoscopic ultrasound |
| Q24628760 | Susceptibility pathways in Fanconi's anemia and breast cancer |
| Q93103921 | Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report |
| Q84951719 | The -409 C/T genotype of PRSS1 protects against pancreatic cancer in the Han Chinese population |
| Q92433763 | The Fanconi Anemia Pathway in Cancer |
| Q37079442 | The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. |
| Q35024542 | The Fanconi anemia pathway and ICL repair: implications for cancer therapy |
| Q28756516 | The Fanconi anemia pathway and ubiquitin |
| Q36867985 | The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. |
| Q26766285 | The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer |
| Q37156381 | The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting |
| Q38661110 | The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes |
| Q33384295 | The ubiquitin system, disease, and drug discovery |
| Q90357642 | Tissue specificity of DNA damage response and tumorigenesis |
| Q57953769 | Update on Familial Pancreatic Cancer |
| Q40020039 | Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: implications for carcinogenesis |
| Q35463399 | Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis |
| Q41063971 | WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner |
Search more.